ANACETRAPIB - Watsons Health


Anacetrapib is a CETP inhibitor being developed to treat hypercholesterolemia (elevated cholesterol levels) and prevent cardiovascular disease.

Anacetrapib reduces the transfer of cholesteryl ester from HDL to LDL and/or VLDL thereby, producing an increase in serum HDL-cholesterol levels and a decrease in serum LDL-cholesterol levels.

The large morbidity and mortality trial with anacetrapib, known as REVEAL and run by researchers at the University of Oxford, is currently ongoing, and full results are expected in 2017.

There is not enough information about the side effects of this drug. However, since it contains inactive ingredients, allergic reaction may be triggered.


The use of this drug has not approved yet due to insufficient data. There is an on-going research about this drug.



Research is still on-going there is no full result about it yet.

Data hasn’t proved yet that increasing HDL (or too much intake of this drug) is bad for someone’s health. Research about this is still on going.

Related Articles


Rilmenidine is an antihypertensive agent that is centrally-acting. It works by activating the central receptors of imidazoline and has an [...]


Quinapril and hydrochlorothiazide both decrease blood pressure via different but complementary mechanisms. Quinapril, a prodrug of quinaprilat, is an ACE [...]


Norethisterone has the usual effects of a progestogen and transforms the endometrium from the secretory to the proliferative process. It [...]